Research Overview
Why the B chain was isolated
Human relaxin-2 is an insulin-family hormone formed from separate A and B chains connected by disulfide bonds. Binding studies identified key arginine and isoleucine residues in the B chain as major contacts for the leucine-rich repeat region of RXFP1. B7-33 was engineered to preserve that interaction surface in a single linear sequence, creating a smaller reagent for structure-activity and receptor-signaling studies. RXFP1 is itself an unusual class A receptor, pairing those leucine-rich repeats with an N-terminal LDLa module reported to be necessary for activation rather than for binding, so ligand engagement and receptor activation can be probed as separate steps.
Chemistry and analytical handling
Having no cysteine removes the disulfide-isomer and chain-scrambling questions that complicate work with two-chain relaxin preparations. The sequence carries five basic residues against a single glutamate, so the peptide is strongly cationic near neutral pH and can adsorb to glass and plastic at low working concentrations. One methionine and one tryptophan make oxidation and light exposure the chemical liabilities most worth controlling, and that single tryptophan is also the only strong ultraviolet chromophore in the molecule.
Functional selectivity
The original characterization compared B7-33 with native relaxin across cells expressing RXFP1. Results were interpreted as signaling bias: the analog could engage ERK1/2-associated pathways strongly in physiologically relevant cells while producing a different cyclic-AMP profile from the two-chain hormone. That profile varies with receptor density and cell background, so direct comparisons require the same expression system, passage and exposure window. Bias is a quantitative claim rather than a descriptive one, and supporting it normally means full concentration–response curves for each pathway, a reference agonist run in the same cells, and an analysis that separates genuine pathway preference from differences in assay amplification.
- RXFP1 binding and activation in engineered and endogenous receptor systems
- Collagen production and matrix-remodeling markers in fibroblast cultures
- Cardiac, pulmonary, renal and scar-associated fibrosis models
- Vascular reactivity and endothelial-function endpoints in isolated tissue and animal work
- Controlled-release coatings and biomaterial interfaces where local fibrotic encapsulation is measured
- Species and orthologue comparisons, since relaxin-family pharmacology is not identical across species
